Get weekly updates on this stock
AB The analyst suggests Abbott Labs is a good value play despite fears surrounding GLP-1 drugs impacting its cardiovascular and diabetes device…
The YouTuber suggests Abbott Laboratories as a potential long-term dividend stock. They note its fair financial statements, a forward P/E ratio on the low end of its 5-year range, and a consistent dividend increase. While acknowledging a recent $20 billion debt increase due to an acquisition, they believe it warrants a deeper dive.
The YouTuber suggests Abbott Laboratories as a potential long-term dividend stock. They note its fair financial statements, a forward P/E ratio on the low end of its 5-year range, and a consistent dividend increase. While acknowledging a recent $20 billion debt increase due to an acquisition, they believe it warrants a deeper dive.
“At first glance, this looks like a company that could be an interesting one to do a deep dive on.”
The analyst suggests Abbott Labs is a good value play despite fears surrounding GLP-1 drugs impacting its cardiovascular and diabetes device segments. He argues that the company's devices are still being used by patients on these drugs and that the stock is undervalued at 23 times forward earnings, compared to its historical average of 29 times, while offering a 2% dividend yield.
The analyst suggests Abbott Labs is a good value play despite fears surrounding GLP-1 drugs impacting its cardiovascular and diabetes device segments. He argues that the company's devices are still being used by patients on these drugs and that the stock is undervalued at 23 times forward earnings, compared to its historical average of 29 times, while offering a 2% dividend yield.
“Abbot Labs ticker ABT is the largest of the five stocks and still down 9% on the year after an 8% rally last month of the largest medical device makers Abbott has taken it the hardest with its focus on cardiovascular and diabetes Solutions.”
A named stock, a clear buy or sell stance, and real reasoning. Passing mentions and hype are filtered out.
Each channel counts once per stock, so a single loud voice can't skew the ranking.
We weigh how many creators agree, how convinced they are, and how recent each call is.
2 finance YouTubers analysed Abbott Labs with qualified reasoning — consensus: Buy, average analysis quality 70/100. This is not financial advice; review the individual analyses and sources above.
Among the channels covering Abbott Labs, 2 are buying and 0 are selling or avoiding — overall Buy.
Only qualified analyses count: a clear buy/sell stance on Abbott Labs with real reasoning (valuation, fundamentals, a catalyst or a chart setup). Passing mentions are excluded.